» Articles » PMID: 18662380

Meta-analysis of Gene Expression Profiles in Breast Cancer: Toward a Unified Understanding of Breast Cancer Subtyping and Prognosis Signatures

Abstract

Introduction: Breast cancer subtyping and prognosis have been studied extensively by gene expression profiling, resulting in disparate signatures with little overlap in their constituent genes. Although a previous study demonstrated a prognostic concordance among gene expression signatures, it was limited to only one dataset and did not fully elucidate how the different genes were related to one another nor did it examine the contribution of well-known biological processes of breast cancer tumorigenesis to their prognostic performance.

Method: To address the above issues and to further validate these initial findings, we performed the largest meta-analysis of publicly available breast cancer gene expression and clinical data, which are comprised of 2,833 breast tumors. Gene coexpression modules of three key biological processes in breast cancer (namely, proliferation, estrogen receptor [ER], and HER2 signaling) were used to dissect the role of constituent genes of nine prognostic signatures.

Results: Using a meta-analytical approach, we consolidated the signatures associated with ER signaling, ERBB2 amplification, and proliferation. Previously published expression-based nomenclature of breast cancer 'intrinsic' subtypes can be mapped to the three modules, namely, the ER-/HER2- (basal-like), the HER2+ (HER2-like), and the low- and high-proliferation ER+/HER2- subtypes (luminal A and B). We showed that all nine prognostic signatures exhibited a similar prognostic performance in the entire dataset. Their prognostic abilities are due mostly to the detection of proliferation activity. Although ER- status (basal-like) and ERBB2+ expression status correspond to bad outcome, they seem to act through elevated expression of proliferation genes and thus contain only indirect information about prognosis. Clinical variables measuring the extent of tumor progression, such as tumor size and nodal status, still add independent prognostic information to proliferation genes.

Conclusion: This meta-analysis unifies various results of previous gene expression studies in breast cancer. It reveals connections between traditional prognostic factors, expression-based subtyping, and prognostic signatures, highlighting the important role of proliferation in breast cancer prognosis.

Citing Articles

Classification of Breast Cancer Through the Perspective of Cell Identity Models.

Iggo R, MacGrogan G Adv Exp Med Biol. 2025; 1464():185-207.

PMID: 39821027 DOI: 10.1007/978-3-031-70875-6_11.


Integrated single-cell analysis reveals distinct epigenetic-regulated cancer cell states and a heterogeneity-guided core signature in tamoxifen-resistant breast cancer.

Fang K, Ohihoin A, Liu T, Choppavarapu L, Nosirov B, Wang Q Genome Med. 2024; 16(1):134.

PMID: 39558215 PMC: 11572372. DOI: 10.1186/s13073-024-01407-3.


Immunohistochemical-Based Molecular Subtypes of Female Breast Cancer: A Retrospective Cross-Sectional Study at Cheikh Khalifa Hospital in Casablanca, Morocco.

Oumnia B, Maladho D, Amanda G, Wafaa K, Fadila G, Mohamed C Cancer Control. 2024; 31:10732748241300655.

PMID: 39528903 PMC: 11555740. DOI: 10.1177/10732748241300655.


Nomograms for predicting recurrence of HER2-positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics.

Zhang X, Kong H, Liu X, Li Q, Fang X, Wang J Cancer Med. 2024; 13(17):e70146.

PMID: 39248049 PMC: 11381954. DOI: 10.1002/cam4.70146.


Advancements in Understanding the Hide-and-Seek Strategy of Hibernating Breast Cancer Cells and Their Implications in Oncology from a Broader Perspective: A Comprehensive Overview.

Al-Ruwishan A, Amer B, Salem A, Abdi A, Chimpandu N, Esa A Curr Issues Mol Biol. 2024; 46(8):8340-8367.

PMID: 39194709 PMC: 11352233. DOI: 10.3390/cimb46080492.


References
1.
Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D . Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005; 24(29):4660-71. DOI: 10.1038/sj.onc.1208561. View

2.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

3.
Korkola J, DeVries S, Fridlyand J, Hwang E, Estep A, Chen Y . Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res. 2003; 63(21):7167-75. View

4.
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W . Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24(23):3726-34. DOI: 10.1200/JCO.2005.04.7985. View

5.
Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View